Search Site

Trends banner

PureHealth posts $137m Q1 net profit

The Group's revenue increased 8 percent YoY.

Borouge Q1 net profit $281 million

The total dividend paid to shareholders in 2024 $1.3bn.

Emirates expects first 777X delivery in H2 2026

Boeing had pushed back the first delivery to 2026 from 2025.

Aramco, unit and Sinopec ink $4bn deal

The two companies will establish a joint venture company.

Etihad unveils new A321LR aircraft

A321LR features First Suite - a private, enclosed space with a sliding door.

Sanofi 2022 net profit at $7.3bn

Sanofi's earnings per share rose by 17.1 percent to US$9 but Sanofi forecast low single-digit growth this year. (AFP)
  • Sanofi is aiming for US$10.9 billion in sales of Dupixent this year.
  • The company's net profit rose by eight percent in 2022.

PARIS, FRANCE – French pharmaceutical giant Sanofi forecast slower earnings growth for 2023 on Friday after profits jumped in 2022 on the back of popular eczema and asthma drug Dupixent.

The company’s net profit rose by eight percent to US$7.3 billion (6.7 billion euros) last year.

Its earnings per share, or profits divided by outstanding shares, rose by 17.1 percent to US$9 (8.26 euros), but Sanofi forecast “low single-digit” growth this year.

Sanofi shares fell following the announcement.

The company’s Dupixent treatment has been a huge success for Sanofi, raking in US$9 billion (8.3 billion euros) in sales last year.

“Dupixent and Vaccines continue to be our leading growth drivers,” Sanofi chief executive Paul Hudson said in a statement.

Sanofi is aiming for US$10.9 billion (10 billion euros) in sales of Dupixent this year.